ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS
First Claim
Patent Images
1. A method for stabilizing inconsistencies associated with opioid dependence, the method comprising:
- a. selecting a patient addicted to an opioid; and
b. administering to the patient an opioid agonist-antagonist for at least 14 days, thereby stabilizing said inconsistencies.
0 Assignments
0 Petitions
Accused Products
Abstract
A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby reducing craving for the opioid in the patient. An opioid agonist-antagonist is administered in a patient needing an average adherence to a treatment protocol of at least 95 percent. A non-injectable formulation containing an agonist-antagonist also is disclosed.
-
Citations
41 Claims
-
1. A method for stabilizing inconsistencies associated with opioid dependence, the method comprising:
-
a. selecting a patient addicted to an opioid; and b. administering to the patient an opioid agonist-antagonist for at least 14 days, thereby stabilizing said inconsistencies. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method for maintaining an opioid-dependent patient on a treatment regimen, the method comprising:
-
a. selecting an opioid-dependent patient in need of an average adherence to the treatment regimen of at least 95 percent; and b. administering to the selected patient a combination of a treatment component and, for at least a month, an opioid receptor agonist-antagonist, whereby the patient'"'"'s average adherence to the treatment regimen, at he end of he at least a month, is no less than 95 percent. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
-
28. A method for maintaining an HIV-infected, opioid-dependent patient on an ARV regimen, the method comprising administering to the patient an ARV component in combination with an opioid receptor agonist-antagonist, wherein the opioid receptor agonist antagonist is administered for no less than a month and, at the end of the at least a month, the patient'"'"'s average adherence to the ARV regimen is at least 95 percent.
-
29. A method for treating an HIV-infected patient, the method comprising:
-
a. selecting an opioid-dependent patient having an average adherence to an ARV regimen that is less that 95 percent; and b. administering to the patient ARV medication in combination with nalbuphine.
-
-
30. A method for maintaining an average compliance to an ARV regiment of at least 95 percent in an opioid-dependent patient, the method comprising administering to the patient ARV medication in combination with an opioid receptor agonist-antagonist.
-
31. A non-injectable formulation for managing opioid-addiction, the formulation comprising:
-
a. an active component including free-base nalbuphine or pharmaceutically acceptable derivative or salt of nalbuphine; and b. a release modifying component, wherein the formulation is in tablet or capsule form. - View Dependent Claims (32, 33, 34, 35)
-
-
36. A transdermal delivery device for managing opioid-addiction, wherein said device includes an opioid agonist-antagonist.
-
37. A non-injectable formulation for managing opioid-addiction, the formulation comprising an agonist-antagonist, wherein the formulation is in the form of a syrup, suppository, powder, inhalable aerosol, sublingual spray, intranasal spray or intranasal aerosol.
-
38. A method for severing an association with injectable opiates, in an opiate using patient, the method comprising administering to the opiate using patient a non-injectable formulation which includes an agonist-antagonist for at least 14 days.
-
39. Use of an agonist-antagonist for the manufacture of a medicament for stabilizing inconsistencies associated with opioid dependence.
- 40. Use of an agonist-antagonist for the manufacture of a medicament for maintaining an opioid-dependent patient on a treatment regimen.
Specification